Welcome to our dedicated page for Amplia Therapeutics news (Ticker: INNMF), a resource for investors and traders seeking the latest updates and insights on Amplia Therapeutics stock.
Amplia Therapeutics develops focal adhesion kinase (FAK) inhibitors for cancer and fibrosis, led by narmafotinib. Company news centers on clinical development of narmafotinib in fibrotic cancers, including pancreatic and ovarian cancer, where updates describe combination studies with standard-of-care chemotherapy, trial data presentations, safety and response analyses, and biomarker work.
Recurring announcements also cover preclinical research in KRAS-mutated cancer models, GMP manufacturing and drug-supply scale-up for narmafotinib, patent and regulatory communications, quarterly activities and cash-flow reporting, and the company’s ASX listing and OTCQB quotation under INNMF.
Amplia Therapeutics (OTCQB:INNMF / ASX:ATX) entered a second-phase preclinical collaboration with Korean drug‑screening company Next & Bio on Dec 19, 2025 to test combination therapy of Amplia’s FAK inhibitor narmafotinib with experimental kRAS inhibitors.
The work uses patient‑derived pancreatic cancer cell models that replicate the tumour environment; initial tests showed promising narmafotinib activity and will be presented at an upcoming scientific conference. The new phase will evaluate potential synergy between FAK and kRAS inhibition and is positioned to support future partnering and commercial opportunities.
Amplia Therapeutics (OTCQB:INNMF) reported an additional confirmed partial response in the ongoing ACCENT trial for metastatic pancreatic cancer, bringing the confirmed objective response rate to 35% (19/55).
The ACCENT trial tests narmafotinib combined with gemcitabine and nab-paclitaxel; the 35% ORR is presented alongside a historical benchmark ORR of 23% from the MPACT trial for gemcitabine and nab-paclitaxel alone. Updated ACCENT data were presented by CEO Dr Chris Burns at the Life Sciences Virtual Investor Forum on December 11 (US ET) / December 12 (AEDT), and the ASX announcement was authorised by the CEO.
Amplia Therapeutics (OTCQB:INNMF) received a Certificate of Grant from the US Patent and Trademark Office for a patent titled A salt and crystal form of a FAK inhibitor, extending protection for the company's clinically developed FAK inhibitor narmafotinib to at least 2040 in the US and other jurisdictions. The grant follows a September 2025 notification of allowance and complements existing patents already granted in Europe, Japan, India, Korea and Australia. The patent specifically protects the particular salt/crystal form of narmafotinib being developed clinically. The company stated protection in additional regions is under review by respective patent offices and said the grants strengthen narmafotinib's long-term intellectual property position.